The Food and Drug Administration has approved a psilocybin-based therapy for treatment-resistant depression, marking the first psychedelic-assisted treatment to receive regulatory approval in the United States. The therapy, developed by Compass Pathways, demonstrated remarkable efficacy in clinical trials.
"This approval represents a paradigm shift in how we approach mental health treatment," said FDA Commissioner Dr. Robert Califf. "For patients who have not responded to existing therapies, this represents a new option that has shown unprecedented results."
The therapy involves a single administration of psilocybin in a clinical setting, accompanied by psychological support before, during, and after the session. Unlike traditional antidepressants, which must be taken daily, the psilocybin treatment showed sustained benefits over at least 12 months.
The treatment will be available only through certified treatment centers with specially trained therapists. The FDA has required extensive safeguards including mandatory monitoring for 24 hours following administration.
"I have spent years trying every medication available, and nothing worked," said trial participant Michael Torres, 34. "The psilocybin therapy didn't just help my depression — it helped me understand myself in a way I never had before."